ASD indicates autism spectrum disorder; GDM, gestational diabetes mellitus; T1D, type 1 diabetes; T2D, type 2 diabetes. ASD includes autistic disorders, Asperger syndrome, or pervasive developmental disorder not otherwise specified.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Xiang AH, Wang X, Martinez MP, Page K, Buchanan TA, Feldman RK. Maternal Type 1 Diabetes and Risk of Autism in Offspring. JAMA. 2018;320(1):89–91. doi:10.1001/jama.2018.7614
Maternal preexisting type 2 diabetes (T2D) and gestational diabetes mellitus (GDM) diagnosed by 26 weeks’ gestation have been associated with increased risk of autism spectrum disorder (ASD) in offspring.1 However, little is known about ASD risk associated with maternal preexisting type 1 diabetes (T1D). We extend previous observations by examining the risk of ASD in offspring associated with maternal T1D, T2D, and GDM.
This retrospective cohort study included singleton children born at 28 to 44 weeks’ gestation in Kaiser Permanente Southern California (KPSC) hospitals from January 1, 1995, through December 31, 2012. Children were tracked through electronic health records from age 1 year until the first date of the following: clinical diagnosis of ASD, last date of continuous KPSC membership, death, or study end date (December 31, 2017). The KPSC institutional review board approved this study and provided waiver of participant consent.
Methods to identify ASD, T2D, and GDM exposure were described previously.1 GDM exposure was divided into diagnosis by or after 26 weeks’ gestation based on a prior finding that risk of ASD was elevated for exposure to GDM by 26 weeks.1 T1D was identified using the algorithm developed for electronic health records data2 and confirmed by prescription of insulin during pregnancy. Potential confounders were birth year, maternal age at delivery, parity, education, self-reported race/ethnicity, median family household income based on residence census tract, history of comorbidity (≥1 diagnosis of heart, lung, kidney, or liver disease; cancer), and child’s sex. Data on maternal smoking and obesity (measured by prepregnancy body mass index [calculated as weight in kilograms divided by height in meters squared]) were available beginning after 2006 (on 36% of the cohort). The missing indicator method was used to additionally adjust for these covariates. Cox regression was used to estimate hazard ratios (HRs) adjusting for potential confounders. All mothers with T1D and T2D, but only 29% of those with GDM, were dispensed antidiabetic medications during pregnancy. Potential risk associated with antidiabetic medication exposure was assessed in the GDM group, adjusting for potential confounders plus the gestational age at GDM diagnosis. SAS Enterprise Guide (SAS Institute), version 5.1, and R (R Foundation), version 3.4.3 (64 bit), were used for data analysis. A 2-sided P value less than .05 was considered significant.
Of 419 425 children (boys, 51%) meeting study criteria, 621 were exposed to maternal T1D, 9453 to maternal T2D, 11 922 to GDM diagnosed by 26 weeks’ gestation, and 24 505 to GDM diagnosed after 26 weeks’ gestation. During a median follow-up of 6.9 years (interquartile range, 3.4-11.9), 5827 children were diagnosed with ASD. Unadjusted average annual ASD incidence rates per 1000 children were 4.4 for exposure to T1D; 3.6 for T2D; 2.9 for GDM by 26 weeks; 2.1 for GDM after 26 weeks; and 1.8 for no diabetes. The Figure depicts the cumulative incidence rates by maternal diabetes exposure groups. Relative to no diabetes exposure, the adjusted HRs for exposure to maternal diabetes were 2.36 (95% CI, 1.36-4.12) for T1D, 1.45 (95% CI, 1.24-1.70) for T2D, 1.30 (95% CI, 1.12-1.51) for GDM by 26 weeks’ gestation, and 0.99 (95% CI, 0.88-1.12) for GDM after 26 weeks. Additional adjustment for maternal smoking during pregnancy and prepregnancy BMI changed results only slightly (Table). Risks were not statistically significantly different between those with vs without antidiabetic medication exposure during pregnancy within the GDM group (adjusted HR, 1.18 [95% CI, 0.97-1.43]; P = .10).
Among the 3 main types of diabetes complicating pregnancy, the risk of ASD in offspring was elevated in mothers with T1D, T2D, and GDM diagnosed by 26 weeks’ gestation compared with no diabetes. These results add new information on T1D and extend previous findings1 for preexisting T2D and GDM. GDM diagnosed after 26 weeks’ gestation was not associated with excess risk compared with no diabetes.
These results suggest that the severity of maternal diabetes and the timing of exposure (early vs late in pregnancy) may be associated with the risk of ASD in offspring of diabetic mothers. The potential role of maternal glycemia; other features of T1D such as autoimmunity and genetic factors3,4; prematurity; and neonatal hypoglycemia5 remains to be explored. Confounding due to paternal risk factors and other intrauterine and postnatal exposures could not be assessed.
Accepted for Publication: May 15, 2018.
Corresponding Author: Anny H. Xiang, PhD, Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Fifth Floor, Pasadena, CA 91101 (email@example.com).
Published Online: June 23, 2018. doi:10.1001/jama.2018.7614
Author Contributions: Drs Xiang and Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Xiang, Feldman.
Acquisition, analysis, or interpretation of data: Xiang, Wang, Martinez, Page, Buchanan.
Drafting of the manuscript: Xiang.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Xiang, Wang.
Obtained funding: Xiang.
Administrative, technical, or material support: Xiang, Martinez.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: This work was partially supported by Kaiser Permanente Southern California Direct Community Benefit funds.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Meeting Presentation: This article was presented at the 78th Scientific Sessions of the American Diabetes Association; June 23, 2018; Orlando, Florida.
Disclaimer: The opinions expressed are solely the responsibility of the authors and do not necessarily reflect the official views of the Kaiser Permanente Community Benefit Funds.
Create a personal account or sign in to: